stockrowAxsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
Follow AXSM
Alert me
Axsome Therapeutics, Inc. (AXSM) Total debt
Axsome Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $122.0M, down 33.6% from $183.7M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $127.3M. Over the past ten years it has ranged from $3.6M (fiscal 2018) to $183.7M (fiscal 2024); the current reading is higher than 80% of that period. Axsome Therapeutics, Inc. ranks 73rd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $122.0M | (33.60%) |
| FY2024 | $183.7M | 3.14% |
| FY2023 | $178.1M | 88.92% |
| FY2022 | $94.3M | 92.01% |
| FY2021 | $49.1M | 1.59% |
| FY2020 | $48.3M | 178.79% |
| FY2019 | $17.3M | 378.88% |
| FY2018 | $3.6M | (45.68%) |
| FY2017 | $6.7M | (29.64%) |
| FY2016 | $9.5M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $127.3M | 0.22% |
| Jun 2026 | $127.0M | 2.66% |
| Mar 2026 | $123.7M | 1.43% |
| Dec 2025 | $122.0M | (0.30%) |
| 36 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| IONS Ionis Pharmaceuticals, Inc. compare | $1.4B |
| MIRM Mirum Pharmaceuticals, Inc. compare | $731.3M |
| LGND Ligand Pharmaceuticals Incorporated compare | $679.9M |
| AXSM Axsome Therapeutics, Inc. | $127.3M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | $106.1M |
| PRAX Praxis Precision Medicines, Inc. compare | $2.8M |
| ABVX Abivax SA Sponsored ADR compare | $1.4M |
| ORKA Oruka Therapeutics, Inc. compare | $301.0K |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on AXSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement